ArticleCureus2022
Secondary Bacterial Infection Rates Among Patients With COVID-19.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Standardized Brazilian green propolis extract (EPP-AF®) in COVID-19 outcomes: a randomized double-blind placebo-controlled trial.Scientific reports · 2023Trial
- Secondary infection in severe COVID-19 patients: clinical and microbial patterns at a tertiary hospital in Vietnam.BMC infectious diseases · 2025Article
- Association between SARS-CoV-2 testing and antibiotic use in Swiss long-term care facilities: a retrospective multicentric study.JAC-antimicrobial resistance · 2025Article
- Predicting infectious etiology and severity in hospitalized pediatric pneumonia using blood cytokine biomarkers.Frontiers in pediatrics · 2025Article
- Nrf2 Regulates Inflammation by Modulating Dendritic Cell-T Cell Crosstalk during Viral-Bacterial Superinfection.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Effect of nasal carriage ofMicrobiology spectrum · 2024Article
- Article
- Evaluation of Secondary Bacterial Infections and Determination of Antibiogram Susceptibility Testing in Hospitalized Patients with COVID-19.Iranian journal of pathology · 2024Article
- Evaluation of Blood Cultures from SARS-CoV-2-Positive and Negative Adult Patients.Healthcare (Basel, Switzerland) · 2023Article
- The Relationship Between Laboratory Findings and Mortality in COVID-19 Patients Requiring Intensive Care.Cureus · 2023Article
- The Assessment of Multiplex PCR in Identifying Bacterial Infections in Patients Hospitalized with SARS-CoV-2 Infection: A Systematic Review.Antibiotics (Basel, Switzerland) · 2023Review
- Phage-Derived Depolymerase: Its Possible Role for Secondary Bacterial Infections in COVID-19 Patients.Microorganisms · 2023Review
- Risk factors and effect on mortality of superinfections in a newly established COVID-19 respiratory sub-intensive care unit at University Hospital in Rome.BMC pulmonary medicine · 2023Article
- COVID-19 and Listeria Meningitis Treated by Ampicillin, Sulfamethoxazole/Trimethoprim and Meropenem.Infection and drug resistance · 2023Article
- Prevalence and mortality rate of healthcare-associated infections among COVID-19 patients: a retrospective cohort community-based approach.Frontiers in public health · 2023Observational
- Article
- Problems Associated with Co-Infection by Multidrug-ResistantHealthcare (Basel, Switzerland) · 2022Review
- Co-Infections and Superinfections in COVID-19 Critically Ill Patients Are Associated with CT Imaging Abnormalities and the Worst Outcomes.Diagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective The aim of this study was to determine the factors and rates of secondary bacterial infections developed in patients after the diagnosis of COVID-19 and antimicrobial susceptibility to guide the empirical treatment and contribute to epidemiological data. Materials and Methods In our study, 1,055 patients diagnosed with COVID-19, hospitalized at Recep Tayyip Erdoğan University Training and Research Hospital, Rize, between the dates March 24, 2020 and December 31, 2020, were recruited. The diagnoses of all patients were confirmed by positive SARS-CoV-2 polymerase chain reaction (PCR) tests. In addition, the blood and respiratory tract cultures of the patients recruited in the study were analyzed retrospectively. Results Ninety-two (8.7%) patients were found to have microbiologically proven respiratory or circulatory tract infections via microbial culture results. Respiratory tract infections were detected as monomicrobial in 44 patients and as polymicrobial in 17 patients, among a total of 61 patients. In addition, 59 (64.1%) patients were male patients, and 33 (35.9%) were female patients. Among the microorganisms grown in blood cultures,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.